Discover tesamorelin dosage trends, reconstitution volumes, and vial size preferences based on real-world WPA calculator data.
Tesamorelin is a stabilized GHRH analog with a well-characterized growth hormone release profile, typically administered via nightly subcutaneous injection. This data shows the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting this GHRH-based peptide.
Tesamorelin (trade name EGRIFTA) is the only GHRH analog in this family that holds an active FDA approval, and the trial program behind it is the most clinically substantive on this site outside the GLP-1 group. Theratechnologies developed tesamorelin specifically to treat HIV-associated lipodystrophy — the abnormal central / visceral fat accumulation that became a hallmark of long-term antiretroviral therapy — and the pivotal evidence is anchored by the Falutz et al. Phase III trial (New England Journal of Medicine, 2007), which enrolled 412 adults with HIV-associated abdominal fat accumulation and randomized them 2:1 to tesamorelin 2mg subcutaneously once daily or placebo for 26 weeks.
Tesamorelin is a growth-hormone-releasing-hormone (GHRH) analog most often sourced for research into visceral-fat reduction and the GH/IGF-1 axis. It is the same molecule sold as the FDA-approved drug Egrifta, and ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
Tesamorelin binds the GHRH receptor on pituitary somatotrophs to stimulate pulsatile release of endogenous growth hormone. Unlike recombinant hGH, this preserves the physiologic GH pulse pattern and the downstream IGF-1 feedback loop, which is associated with a different visceral-adiposity profile than direct hGH replacement.
The pivotal Phase 3 trials (Falutz et al., NEJM 2007; Stanley et al., JAMA 2014) demonstrated ~15–18% reductions in visceral adipose tissue at 26 weeks in HIV-associated lipodystrophy. Ongoing investigator-initiated work has extended tesamorelin into non-HIV NAFLD/MASLD populations.
Tesamorelin has a reported half-life of ~26–38 min, and the dose intervals researchers model most often fall around once daily. Very short half-life. Tesamorelin acts as a pulse that triggers an endogenous GH release; there is no plasma buildup, so timing (typically bedtime) matters more than steady-state level. It is catalogued under Weight Loss on WPA.
6,908 Tesamorelin reconstitution calculations have been logged by the WPA community. The most common dose entered is 1mg (2,309 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (4,213 sessions). The most common dosing frequency is 5x/week (657 logged protocols), followed by daily (7x/week) (650).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.